Coherus Oncology

Coherus Oncology is a leading biotechnology research company dedicated to extending the lives of patients through innovative oncology solutions. With a commitment to advancing cancer treatment, Coherus Oncology focuses on the development and commercialization of next-generation therapies. The company's approved PD-1 inhibitor, LOQTORZI, marks a significant step forward in cancer care.

Located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US, Coherus Oncology is strategically expanding the use of LOQTORZI in NPC and advancing the development of new indications. The company's pipeline includes promising mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Furthermore, Coherus Oncology is located on 4014 Camino Ranchero
Unit A
Camarillo, California 93012, US.

Coherus Oncology is driving synergies through proprietary combinations, including first-in-class anticancer agents. The company's forward-thinking approach positions it as a key player in the biotechnology and immuno-oncology space. We invite the management team at Coherus Oncology to create a customized and exclusive company showcase and product listing on our platform.